Daiichi Sankyo expands its OTC reach; Mylan to prohibit sales of drug for executions;

@FiercePharma: MSF campaigns at UN summit meeting to ease pressure on India's drug IP policies. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: Obstacles aside, Boehringer sees class-topping prospects for Ofev, Spiolto. FiercePharmaMarketing story | Follow @CarlyHFierce

Daiichi Sankyo has acquired ImCo, a growing mail-order OTC drug and cosmetics maker. Report

Mylan ($MYL), bending to pressure, has agreed like many other drugmakers to write contracts that prevent distributors from selling its drug rocuronium bromide for use in lethal injections. Story

The maker of the first liquid dose aspirin is looking for a partner. Report

French vaccine maker Abivax is conducting clinical trials on a hepatitis C vaccined developed in Cuba. Story

Medical Device News

@FierceMedDev: Illumina expands in China with cancer Dx deal. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Study: Oraya radiation tech reduces need for eye injections in AMD patients. Article | Follow @VarunSaxena2

**@EmilyWFierce:**ICYMI from FiercePharma: U.K. patient group demands government override Roche's Kadcyla patents. Article | Follow @EmilyWFierce

Google sees independent startups as key to new Alphabet reorganization. Report

NIH's BRAIN initiative, philanthropic Kavli Foundation provide $185M to study brain science. More

Siemens nabs Abbott SVP to run healthcare in North America. Article

Biotech News

@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech

@JohnCFierce: Ladies and gentlemen, the 2015 Fierce 15. Special report | Follow @JohnCFierce

**@DamianFierce:**Today's the FDA decision deadline for Keytruda's lung cancer app. Can't wait to see the TV ad. | Follow @DamianFierce

XenoPort hits reset after a psoriasis setback, cutting jobs and bailing on R&D. Report

Regeneron inks a $325M deal, selling Asian rights to a pain treatment. Story

Sanofi steps deeper into RNAi work, opts in on Alnylam hemophilia drug. Article